glp 1 pcos Benefits of administering GLP-1 analogs to patients with polycystic ovary syndrome, considering their effect on adipose tissue m GLP-1 agonists and PCOS weight

Among the marketed large molecule injectable GLP-1 agonists, semaglutide, apart from weight-loss, is being studied for kidney disease and tirzepatide (a dual GLP-1 and GIP receptor agonist) is being evaluated for sleep apnea in Ph 3 clinical trials

These drugs effectively lower blood glucose levels and provide cardiovascular and renal benefits, making them a preferred treatment option in diabetes care

What to eat to balance your blood sugar and lose weight

From nausea to constipation, heres how to handle GLP-1 side effects safely and effectively.

The global incretin-based drugs market was valued at USD 39.4 billion in 2025 and is projected to grow from USD 41.6 billion in 2026 to USD 72.6 billion by 2035, expanding at a CAGR of 6.4% between 2026 and 2035, driven by the rising prevalence of type 2 diabetes mellitus.

This review summarizes current evidence on the nutritional implications of GLP1-based pharmacotherapy in adults with obesity, including common gastrointestinal adverse events, reduced energy intake, potential macro and micronutrient inadequacies, and risks of lean mass loss